1. Adam D. Mental health: on the spectrum. Nature 2013;496:416–428.
2. Shorter E. The History of DSM. In: Paris J, editor. Making the DSM-5: Concepts and Controversies. New York: Springer Nature, 2013, p. 3–20.
3. Sadler JZ. Considering the Economy of DSM Alternatives. In: Paris J, editor. Making the DSM-5: Concepts and Controversies. New York: Springer Nature, 2013, p. 21–38.
4. Insel TR. Next-generation treatments for mental disorders. Sci Transl Med 2012;4:155psc19.
5. Insel TR, Cuthbert BN. Brain disorder? Precisely. Science 2015;348:499–500.
6. Miller G. Beyond DSM: seeking a brain-based classification of mental illness. Science 2010;327:1437
7. Whooley O, Horowitz AV. The Paradox of Professional Success: Grand Ambition, Furious Resistances, and the Derailment of the DSM-5 Revision Process. New York: Springer Nature; 2013, p. 75–92.
8. Assembly of the American Psychiatric Association. Motion on cross-cutting dimensions and severity scales. In: Passed at the annual meeting of American Psychiatric Association; New York. 2012.
9. Frances A. Diagnosing the DSM. The New York Times. 11 May 2012; 19.
10. Kupfer DJ, Regier DA. Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5. Am J Psychiatry 2011;168:672–674.
11. Uher R, Perlis RH, Henisberg N, Zobel A, Rietschel M, Mors O, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: Replicable evidence for interest-activity symptoms. Psychol Med 2012;42:967–980.
12. Park SC, Kim YK. Depression in DSM-5: Changes, tControversies and Future Direcion. In: Kim YK, editor. Understanding Depression: Volume 2. Clinical Manifestations, Diagnosis and Treatment. New York: Springer Nature, 2018, p. 3–14.
13. Ghaemi SN. Understanding Mood Disorders: Karl Jaspers’ Biological Existentialism. In: Stanghellini G, Fuchs T, editor. One Century of Karl Jaspers’ General Psychopathology. Oxford: Oxford University Press, 2013, p. 245–257.
14. Engstrom EJ, Kendler KS. Emil Kraepelin: icon and reality. Am J Psychiatry 2015;172:1190–1196.
15. Kendler KS, Engrom EJ. Criticisms of Kraepelin’s psychiatric nosology: 1896-1927. Am J Psychiatry 2018;175:316–326.
17. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009;373:234–239.
20. Berk M, Berk L, Moss K, Dodd S, Malhi GS. Diagnosing bipolar disorder: how can we do it better? Med J Aust 2016;184:459–462.
21. Etain B, Lajnef M, Bellivier F, Mathiey F, Raust A, Cochet B, et al. Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States. J Clin Psychiatry 2012;73:e561–e566.
22. Moller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, et al. DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequence - Part 1: general aspects and paradigmatic discussion of depressive disorders. Eur Arch Psychiatry Clin Neurosci 2015;265:5–18.
23. Zimmerman M, Chelminski I, Young D, Dalrymple J, Matinez JH. A clinically useful self-report measure of the DSM-5 mixed features specifier of major depressive disorder. J Affect Disord 2014;168:357–362.
24. Koulopoulos A, Sani G, Ghaemi SN. Mixed features of depression: why DSM-5 is wrong (and so was DSM-IV). Br J Psychiatry 2013;203:3–5.
28. Greene GM. The relationship between depression and hopelessness: implications for current theories of depression. Br J Psychiatry 1993;154:650–659.
29. Beck AT, Steer RA, Beck JS, Newman CF. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat Behav 1993;23:139–145.
30. Joiner TE Jr, Steer RA, Abramson LY, Alloy LB, Metalsky GI, Schmidt NB. Hopelessness depression as a distinct dimension of depressive symptoms among clinical and non-clinical samples. Behav Res Ther 2001;39:523–536.
31. Zisook S, Corruble E, Duan N, Iglewicz A, Karam EG, Lanouette N, et al. The bereavement exclusion and DSM-5. Depress Anxiety 2012;29:425–443.
32. Bandini J. The medicalization of bereavement: (Ab)normal grief in the DSM-5. Death Stud 2015;39:347–352.
33. Pies RW. The bereavement exclusion and DSM-5: an update and commentary. Innov Clin Neurosci 2014;11:19–22.
34. Zimmerman M, Galione JN, Chelminski I, McGlinchery JB, Young D, Dalrymple K, et al. A simpler definition of major depressive disorder. Psychol Med 2010;40:451–457.
35. Østergaard SD, Jensen SOW, Bech P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr Scand 2011;124:495–496.
36. Zimmerman M, Ellison W, Young D, Chelminski I, Dalrymple K. How many different ways do patients meet the diagnostic criteria for major depressive disorder. Compr Psychiatry 2015;56:29–34.
37. Park SC, Kim JM, Jun TY, Lee MS, Kim JB, Yim HW, et al. How many different symptom combinations fulfill the diagnostic criteria for major depressive disorder?: results from the CRESCEND study. Nord J Psychiatry 2017;71:217–222.
38. Rosenman S, Nasti J. Psychiatric diagnoses are not mental processes: Wittgenstein on conceptual confusion. Aust N Z J Psychiatry 2012;46:1046–1052.
39. Wittgenstein L. Philosophical Investigations. (German Text, with a Revised English Translation, Trans GEM Anscombe). 3rd Edition. Oxford: Blackwell; 2001.
41. Fried EI. Moving forward: how depression heterogeneity hinders progress in treatment and research. Expert Rev Neurother 2017;17:423–425.
43. Fried EI, Nesse RM. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J Affect Disord 2015;172:96–102.
44. Hieronymus F, Emilsson JF, Nilsson S, Eriksson E. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression. Mol Psychiatry 2016;21:523–530.
45. Persons JB. The advantages of studying psychological phenomena rather than psychiatric diagnoses. Am Psychol 1986;41:1252–1260.
46. Contreas A, Nieto I, Valiente C, Espinosa R. The study of psychopathology from the network analysis perspective: a systematic review. Psychother Psychosom 2019;88:71–83.
47. Fried EI, Epskamp S, Nesse RM, Tuerlinckx F, Borsboom D. What are ‘good’ depressive symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2016;189:314–320.
48. Opsahl T, Agneessens F, Skvoretz J. Node centrality in weighted networks: generalizing degrees and shortest paths. Soc Netw 2010;32:245–251.
49. van Borkulo C, Boschloo L, Borsboom D, Pennix BW, Waldorp LJ, Schoevers RA. Association of symptom network structure with the course of longitudinal depression. JAMA Psychiatry 2015;72:1219–1226.
50. Madhoo M, Levine SZ. Network analysis of the Quick Inventory of Depressive Symptomatology: Reanalysis of the STAR*D clinical trial. Eur Neuropsychopharmacol 2016;26:1768–1774.
51. Cramer AO, Borsboom D, Aggen SH, Kendler KS. The psychopathology of dysphoric episodes: differential impact of stressful life events on the pattern of depressive symptom inter-correlations. Psychol Med 2012;42:957–965.
53. McWilliams LA, Sarty G, Kowal J, Wilson KG. A network analysis of depressive symptoms individuals seeking treatment for chronic pain. Clin J Pain 2017;33:899–904.
54. Park SC, Choi J. Issues in the Classification of Psychotic Depression. In: Kim YK, editor. Major Depressive Disorder: Risk Factors, Characteristics and Treatment Options. New York: NOVA Science Publishers Inc, 2017, p. 49–67.
55. Østergaard SD, Rothschild AJ, Uggerby P, Munk-Jørgensen P, Bech P, Mors O. Considerations on the ICD-11 classification of psychotic depression. Psychother Psychosom 2012;81:135–144.
57. Glassman AH, Roose SP. Delusional depression: a distinct clinical entity? Arch Gen Psychiatry 1981;138:831–833.
58. Lykouras E, Malliara D, Christoodoulou GN, Papakostas Y, Voulgari A, Tzonou A, et al. Delusional depression: phenomenology and response to treatment. A prospective study. Acta Psychiatr Scand 1986;73:324–329.
59. Frances A, Brown RP, Kocsis JH, Mann JJ. Psychotic depression: a separate entity? Am J Psychiatry 1981;138:831–833.
60. Zaninotto L, Gulielmo R, Calati R, Ioime L, Camardes G, Janiri L, et al. Cognitive markers of psychotic unipolar depression: a meta-analytic study. J Affect Disord 2015;174:580–588.
61. Hill SK, Keshavan MS, Thase ME, Sweeney JA. Neuropsychological dysfunction in antipsychotic-naïve first-episode unipolar psychotic depression. Am J Psychiatry 2014;161:996–1003.
62. Anton RF. Urinary free cortisol in psychotic depression. Biol Psychiatry 1987;22:24–34.
63. Nelson JC, Davis JM. DST studies in psychotic depression: a meta-analysis. Am J Psychiatry 1997;154:1497–1503.
64. Rosthschild AJ, Schatzberg AF, Rosenbaum AH, Stahl JB, Cole JO. The dexamethasone suppression test as a discriminator among subtypes of psychotic patients. Br J Psychiatry 1982;141:471–474.
65. Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB, et al. The dexamethasone suppression test: Identification of subtypes of depression. Am J Psychiatry 1983;140:88–91.
66. Kim DK, Kim BL, Sohn SE, Lim SW, Na DG, Paik CH, et al. Candidate neuroanatomic substrates of psychosis in old-aged depression. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:793–807.
67. Salokangas RK, Cannon T, van Erp T, Ilonen T, Taiminen T, Karlsson H, et al. Structural magnetic resonance imaging in patients with first-episode schizophrenia, psychotic and severe non-psychotic depression and healthy controls: results of the schizophrenia and affective psychoses (SAP) project. Br J Psychiatry Suppl 2012;43:S58–S65.
68. Simpson S, Baldwin RC, Jackson A, Burns A. The differentiation of DSM-III-R psychotic depression in later life from nonpsychotic depression: comparisons of brain changes measured by multispectral analysis of magnetic resonance brain images, neuropsychological findings, and clinical features. Biol Psychiatry 1999;45:193–204.
69. Cubells JF, Price LH, Meyers BA, Anderson GM, Zabetian CP, Alexopoulos GS, et al. Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry 2002;51:358–364.
70. Meyers BS, Alexopoulos GS, Kakuma T, Tirumalasetti F, Gabriele M, Alpert S, et al. Decreased dopamine beta-hyrodoxylase activity in unipolar geriatirc delusional depression. Biol Psychiatry 1999;45:448–452.
71. Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined analysis of mifepristone for psychotic depression: plasma levels associated with clinical response. Biol Psychiatry 2018;84:46–54.
72. Østergaard SD, Bille J, Søltoft-Jensen H, Lauge N, Bech P. The validity of severity-psychosis hypothesis in depression. J Affect Disord 2012;140:48–56.
73. Maj M, Pirozzi R, Magliano L, Fiorillo A, Bartoli L. Phenomenology and prognostic significance of delusions in major depressive disorder: a 10-year prospective follow-up study. J Clin Psychiatry 2007;68:1411–1417.
74. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in general population. Am J Psychiatry 2002;159:1855–1861.
75. Tamminga CA, Sirovatka PJ, Regier DA, van Os J. Deconstructing Psychosis: Refining the Research Agenda for DSM-V. Washington, D.C: American Psychiatric Association; 2010.
77. Østergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, et al. Measuring psychotic depression. Acta Psychiatr Scand 2014;129:211–220.
79. Østergaard SD, Pedersen C, Uggerby P, Munk-Jørgensen P, Rothschild AJ, Larsen JI, et al. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord 2015;173:261–268.
80. Østergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Vermeulen T, et al. Establishing the cut-off score for remission and severity-ranges on the psychotic depression assessment scale (PDAS). J Affect Disord 2016;190:111–114.
81. Leadholm AK, Rothschild AJ, Nolen WA, Bech P, Munk-Jørgensen P, Østergaard SD. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord 2013;145:214–220.
82. Park SC, Choi J, Kim JM, Jun TY, Kim JB, Yim HW, et al. Is the psychotic depression assessment scale a useful diagnostic tool?: the CRESCEND Study. J Affect Disord 2014;166:79–85.
83. Park SC, Østergaard SD, Choi J, Kim JM, Jun TY, Lee MS, et al. Is the BPRS-5 subscale of the psychotic depression assessment scale a reliable screening tool for psychotic depression?: results from the CRESCEND Study. J Affect Disord 2015;174:188–191.
85. Goldberg D, Kendler KS, Sirovata PJ, Regier DA. Diagnostic Issues in Depression and Generalized Anxiety Disorder: Refining the Research Agenda for DSM-V. Washington, D.C: American Psychiatric Association; 2010.
86. Starcevic V, Portman ME. The status quo as a good outcome: how the DSM-5 diagnostic criteria for generalized anxiety disorder remained unchanged from the DSM-IV criteria. Aust N Z J Psychiatry 2013;47:995–997.
87. Karlsson B, Sistrom R, Ostling S, Waern M, Borjesson-Hanson A, Skoog I. DSM-IV and DSM-5 prevalence of social anxiety disorder in a population sample of older people. Am J Geriatr Psychiatry 2016;24:1237–1245.
88. Gaspesz R, Lamers F, Kent JM, Beekman AT, Smit JH, van Hemert AM, et al. Longitudinal predictive validity of the DSM-5 anxious distress specifier for clinical outcomes in a large cohort of patients with major depressive disorder. J Clin Psychiatry 2017;78:207–213.